Publications by authors named "S Fancelli"
Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients' survival.
View Article and Find Full Text PDFArticle Synopsis
- Hyponatremia is known to indicate survival chances in metastatic non-small cell lung cancer (mNSCLC), but the effects of normal sodium levels had not been previously studied until this research.
- The study involved 88 mNSCLC patients treated with immune checkpoint inhibitors (ICIs) and analyzed how sodium levels affected their treatment responses and overall survival.
- Results showed that patients with sodium levels ≥140 mEq/L had significantly better progression-free survival (7.0 months vs. 2.1 months) and overall survival (15.6 months vs. 6.8 months), suggesting low sodium levels are linked to worse outcomes in mNSCLC.
Globally, more than 1 million new cases of gastric cancer were estimated in 2020, ranking fourth in cancer mortality. Currently although in resectable gastric cancer and esophagogastric junction (EGJ) adenocarcinoma a perioperative triplet chemotherapy regimen including a fluoropyrimidine, a platinum compound and docetaxel (FLOT) demonstrated a better overall survival, the survival rate is still very low, and a massive effort is still required to improve clinical prognosis. High microsatellite instability (MSI-H) status in gastric cancer is a favorable prognostic factor but poor data are available on its predictive role for perioperative FLOT chemotherapy in resectable gastric cancer.
View Article and Find Full Text PDFArticle Synopsis
- - The RAS gene family includes genes like KRAS that control cell growth, and mutations in KRAS are commonly associated with various cancers, leading to unchecked tumor growth.
- - Recent clinical trials have shown that many NSCLC patients are resistant to treatments targeting KRAS mutations, particularly G12C, due to factors like co-mutations and secondary resistance.
- - The paper reviews recent findings on KRAS resistance mechanisms and how KRAS interacts with the tumor microenvironment, highlighting the potential of immune checkpoint inhibitors.
Background: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown.
Methods: Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED).